About Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 (HACD1) is a protein
from Homo sapiens identified by UniProt accession
B0YJ81, 288 residues long.
MolForge cross-references it against 0 known binders and
63 disease associations.
Target properties
| Protein name | Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 |
| UniProt accession | B0YJ81 |
| Gene | HACD1 |
| Organism | Homo sapiens |
| Length | 288 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (63)
Diseases linked to this target (Open Targets).
- congenital myopathy · score 0.46
- congenital fiber-type disproportion myopathy · score 0.37
- genetic disorder · score 0.18
- glycogen storage disease due to lactate dehydrogenase H-subunit deficiency · score 0.07
- age-related macular degeneration · score 0.07
- X-linked retinal dysplasia · score 0.06
- Familial exudative vitreoretinopathy · score 0.06
- retinitis pigmentosa · score 0.06
- aspartate aminotransferase measurement · score 0.06
- alcohol sensitivity, acute · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-B0YJ81-F1 | alphafold | PREDICTED | 75.04 | — |
Amino-acid sequence (288 residues)
MGRLTEAAAA GSGSRAAGWA GSPPTLLPLS PTSPRCAATM ASSDEDGTNG GASEAGEDRE APGERRRLGV LATAWLTFYD IAMTAGWLVL AIAMVRFYME KGTHRGLYKS IQKTLKFFQT FALLEIVHCL IGIVPTSVIV TGVQVSSRIF MVWLITHSIK PIQNEESVVL FLVAWTVTEI TRYSFYTFSL LDHLPYFIKW ARYNFFIILY PVGVAGELLT IYAALPHVKK TGMFSIRLPN KYNVSFDYYY FLLITMASYI PLFPQLYFHM LRQRRKVLHG EVIVEKDD
Explore Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets